Expression of HER2 and its association with AP-2 in breast cancer

European Journal of Cancer

Volumn 40, Issue 10, 2004, Pages 1485-1495

  Pellikainen, J ^a,b   Naukkarinen, A ^b   Ropponen, K ^b   Rummukainen, J ^b   Kataja, V ^b   Kellokoski, J ^b   Eskelinen, M ^b   Kosma, V M ^a,b,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

AP 2; Breast cancer; CISH; HER2; Prognosis; Prospective

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR AP 2;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; FEMALE; FINLAND; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CELL DIVISION; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 2942552450     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.020     Document Type: Article

References (48)

1. Burden S., Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron. 18:1997;847-855
2. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410:1997;83-86
3. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer. 37(Suppl 4):2001;S3-S8
4. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655
5. Hollywood D.P., Hurst H.C. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J. 12:1993;2369-2375
6. Kraus M.H., Popescu N.C., Amsbaugh S.C., King C.R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6:1987;605-610
7. Hurst H.C. Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res. 3:2001;395-398
8. Ross J.S., Fletcher J.A. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 112:1999;S53-S67
9. Koeppen H.K., Wright B.D., Burt A.D., et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 38:2001;96-104
10. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712
11. Ross J.S., Fletcher J.A. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 112:1999;S53-S67
12. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182
13. Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19:2000;6115-6121
14. Vogel C., Cobleigh M.A., Tripathy D., et al. First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur. J. Cancer. 37(Suppl 1):2001;25-29
15. Bosher J.M., Williams T., Hurst H.C. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc. Natl. Acad. Sci. USA. 92:1995;744-747
16. Bosher J.M., Totty N.F., Hsuan J.J., Williams T., Hurst H.C. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene. 13:1996;1701-1707
17. Vernimmen D., Begon D., Salvador C., Gofflot S., Grooteclaes M., Winkler R. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem. J. 370:2003;323-329
18. Gee J.M., Robertson J.F., Ellis I.O., Nicholson R.I., Hurst H.C. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J. Pathol. 189:1999;514-520
19. Turner B.C., Zhang J., Gumbs A.A., et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res. 58:1998;5466-5472
20. Zhao F., Satoda M., Licht J.D., Hayashizaki Y., Gelb B.D. Cloning and characterization of a novel mouse AP-2 transcription factor, AP-2delta, with unique DNA binding and transactivation properties. J. Biol. Chem. 276:2001;40755-40760
21. Hilger-Eversheim K., Moser M., Schorle H., Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene. 260:2000;1-12
22. Gershenwald J.E., Sumner W., Calderone T., Wang Z., Huang S., Bar-Eli M. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene. 20:2001;3363-3375
23. Huang S., Jean D., Luca M., Tainsky M.A., Bar-Eli M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 17:1998;4358-4369
24. Karjalainen J.M., Kellokoski J.K., Eskelinen M.J., Alhava E.M., Kosma V.M. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J. Clin. Oncol. 16:1998;3584-3591
25. Zhang J., Brewer S., Huang J., Williams T. Overexpression of transcription factor AP-2alpha suppresses mammary gland growth and morphogenesis. Dev. Biol. 256:2003;127-145
26. Pellikainen J., Kataja V., Ropponen K., et al. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin. Cancer Res. 8:2002;3487-3495
27. Tanner M., Gancberg D., Di Leo A., et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 157:2000;1467-1472
28. Mitrunen K., Sillanpaa P., Kataja V., et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis. 22:2001;827-829
29. Mitrunen K., Jourenkova N., Kataja V., et al. Glutathione S-transferase M1, M3, P1 and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol. Biomarkers Prev. 10:2001;229-236
30. Mitrunen K., Jourenkova N., Kataja V., et al. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9:2000;1343-1348
31. Mitrunen K., Jourenkova N., Kataja V., et al. Polymorphic catechol-o-methyltransferase gene and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 10:2001;635-640
32. The Finnish Breast Cancer Group. National guidelines for the diagnosis and treatment of breast cancer, Ed. 2 (in finnish). Helsinki, Copy-Set Oy, 1996
33. Hermanek P., Sobin L.H. International Union Against Cancer. TNM Classifiction of Malignant Tumours. 4th ed. 1992;103-109 Springer, Berlin. (2nd Revision)
34. Pellikainen M.J., Pekola T.T., Ropponen K.M., et al. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation and prognosis. J. Clin. Pathol. 56:2003;214-220
35. Marks J.R., Humphrey P.A., Wu K., et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann. Surg. 219:1994;332-341
36. Zhao J., Wu R., Au A., Marquez A., Yu Y., Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod. Pathol. 15:2002;657-665
37. Arnould L., Denoux Y., MacGrogan G., et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br. J. Cancer. 88:2003;1587-1591
38. Dandachi N., Dietze O., Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab. Invest. 82:2002;1007-1014
39. Borg A., Baldetorp B., Ferno M., Killander D., Olsson H., Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 6:1991;137-143
40. Ferrero-Pous M., Hacene K., Bouchet C., Le D.V., Tubiana-Hulin M., Spyratos F. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin. Cancer Res. 6:2000;4745-4754
41. Menard S., Balsari A., Casalini P., et al. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin. Cancer Res. 8:2002;520-525
42. Hoff E.R., Tubbs R.R., Myles J.L., Procop G.W. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am. J. Clin. Pathol. 117:2002;916-921
43. Porter P.L., Garcia R., Moe R., Corwin D.J., Gown A.M. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer. 68:1991;331-334
44. Timms J.F., White S.L., O'Hare M.J., Waterfield M.D. Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene. 21:2002;6573-6586
45. Gilbertson R.J., Perry R.H., Kelly P.J., Pearson A.D., Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 57:1997;3272-3280
46. Zeng Y.X., Somasundaram K., el-Deiry W.S. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat. Genet. 15:1997;78-82
47. Kannan P., Buettner R., Chiao P.J., Yim S.O., Sarkiss M., Tainsky M.A. N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation. Genes Dev. 8:1994;1258-1269
48. Tellez C., McCarty M., Ruiz M., Bar-Eli M. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J. Biol. Chem. 278:2003;46632-46642